Biologics and biosimilars in Brazil – the strategic questions -

By Marisa Moura Momoli

May 29, 2020

Biologics and biosimilars in Brazil – the strategic questions

Our partners Anderson Ribeiro, Aline Ferreira and Priscila Kashiwabara and patent specialist Marisa Momoli authored the chapter "Biologics and biosimilars in Brazil – the strategic questions". This article first appeared in IAM Life Sciences: Key issues for senior life sciences executives 2020, a supplement to IAM, published by Law Business Research – IP Division.

Click below to access the full chapter.

See file

Back

Marisa Moura Momoli

Last by Marisa Moura Momoli

March 28, 2022

Brazilian PTOs publishes a technical note providing guidance on the patentability of elite events

On March 17, 2022, the BPTO released the INPI/CPAPD technical note No. 01/2022, which provides guidance on the patentability of inventions involving … Brazilian PTOs publishes a technical note providing guidance on the patentability of elite events

February 14, 2022

Life sciences patent eligibility in Latin America: a guide

Patents are critical to the life sciences industry and often spark intense and heated debate. To be successful, one key strategy that … Life sciences patent eligibility in Latin America: a guide

February 8, 2022

News on apostille of letters-patent retroactively affected by the Direct Plea of Unconstitutionality 5,529

On February 8th, 2022, the Brazilian Patent Office reported the decision to apostille letters-patent when the patent protects subject-matter going beyond the … News on apostille of letters-patent retroactively affected by the Direct Plea of Unconstitutionality 5,529